Cordis/Advanced Cell Technology
This article was originally published in The Gray Sheet
Executive Summary
The Biologics Delivery Systems group of Johnson & Johnson/Cordis will supply catheters for administering Advanced Cell Technology's stem cell therapy for treatment of heart failure in a Phase II clinical trial, ACT announces March 5. The myoblast therapy involves transplanting stem cells derived from a patient's leg muscle into scarred heart tissue to help rebuild the heart muscle and prevent progression of congestive heart failure. The trial will use the Cordis group's NOGA cardiac navigation system and MyoStar injection catheter. Medtronic and Genzyme are also collaborating on catheter delivery of myoblast treatment (1"The Gray Sheet" June 7, 2004, p. 13)
You may also be interested in...
Medtronic Gets To Heart Of Cell Therapy Through Genzyme Collaboration
Medtronic will draw on expertise from its three cardiac-related divisions to aid Genzyme in the development of a catheter-delivered cell therapy for cardiovascular disease
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.